Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)

Latest News

Health Care Stocks: A Year in Review and Predictions for 2015

Health Care Stocks: A Year in Review and Predictions for 2015

In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?

'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

The trading panel looked at banks and the top buy and sell candidates for right now.

Cramer: Every Which Way But Short

Cramer: Every Which Way But Short

In theory, there should be plenty of shorting opportunities.

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics" The main beneficiary of a recent acquisition of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) by Merck & Co., I...

Idenix Pharmaceuticals Inc Stock Sees Short Interest Fall 16%

Idenix Pharmaceuticals Inc Stock Sees Short Interest Fall 16%

The most recent short interest data has been released by the NASDAQ for the 06/13/2014 settlement date, which shows a 3,181,609 share decrease in total short interest for Idenix Pharmaceuticals Inc , to 16,866,953, a decrease of 15.87% since 05/30/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc.

This Biotech Stock Could Be the Next Big Short Squeeze

This Biotech Stock Could Be the Next Big Short Squeeze

The biotech sector is back in play on Wall Street in a big way, and anyone short the sector has to be feeling nervous

Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits

Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits

Investors see a bidding war in the 233% premium Merck paid for Idenix. And they believe losing bidders may seek to acquire competing biotechs with promising hepatitis C drugs in the pipeline.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of Idenix Pharmaceuticals, Inc. And Its Board Of Directors In Connection With The Sale Of The Company To Merck

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of Idenix Pharmaceuticals, Inc. And Its Board Of Directors In Connection With The Sale Of The Company To Merck

Levi & Korsinsky is investigating the Board of Directors of Idenix Pharmaceuticals, Inc.

'Fast Money' Recap: Markets Start Another Week on Positive Note

'Fast Money' Recap: Markets Start Another Week on Positive Note

The trading panel looked at the new post-split Apple and whether it's worth the investment.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc.

Jim Cramer's 'Mad Money' Recap: What Was Jim Cramer Thinking?

Jim Cramer's 'Mad Money' Recap: What Was Jim Cramer Thinking?

The fighting over Hillshire Brands makes Cramer wonder if he hasn't underestimated the valuation of a number of acquisition targets.

No News Is OK News as Markets Hold Onto Record Gains

No News Is OK News as Markets Hold Onto Record Gains

With a busy week of economic data behind us, U.S. markets were little changed Monday in the absence of any market-moving catalyst.

Why Idenix Pharmaceuticals (IDIX) Exploded to a One-Year High Today (Update)

Why Idenix Pharmaceuticals (IDIX) Exploded to a One-Year High Today (Update)

Idenix Pharmaceuticals (IDIX) shares exploded to a new 52-week high of $24.21 on Monday amid news that Merck (MRK) would purchase the biotechnology company for $3.85 billion.

4 Big Stocks on Traders' Radars

4 Big Stocks on Traders' Radars

Here's how to trade some of the most active stocks on the market today.

Idenix Pharmaceuticals Trust Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate The Acquisition By Merck

Idenix Pharmaceuticals Trust Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate The Acquisition By Merck

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Idenix...

Merck Buys Idenix -- Could Inovio or MannKind Be Next?: StockTwits

Merck Buys Idenix -- Could Inovio or MannKind Be Next?: StockTwits

Investors speculate that Merck may buy Inovio or MannKind in the wake of its Idenix acquisition, despite CEO statements that the company would rather grow shareholder value with internal innovation.

HCV Players Moving After Merck Buys Idenix

HCV Players Moving After Merck Buys Idenix

Shares of several companies that have developed hepatitis C, or HCV, treatments are rising after one such company, Idenix, agreed to be acquired by Merck.

Merck Adds HCV Candidates with Idenix Buy

Merck Adds HCV Candidates with Idenix Buy

Merck is making an all-cash $3.85 billion tender offer for Cambridge, Mass.-based Idenix Pharmaceuticals in a strategic bid to strengthen Merck's hepatitis C drug program.

Achillion Pharma Might be Next Hep C Takeout Target

Achillion Pharma Might be Next Hep C Takeout Target

Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.